• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

端粒酶表达作为预测直肠癌放疗反应的标志物。

Telomerase expression as a predictive marker of radiotherapy response in rectal cancer.

机构信息

Department of Anatomical Pathology, Liverpool Hospital, and Discipline of Pathology and Cancer Biology Laboratory, School of Medicine, University of Western Sydney, New South Wales, Australia.

出版信息

Pathology. 2012 Apr;44(3):209-15. doi: 10.1097/PAT.0b013e3283511cd5.

DOI:10.1097/PAT.0b013e3283511cd5
PMID:22406483
Abstract

AIMS

To investigate telomerase as a predictive marker of radiotherapy response in rectal cancer.

METHODS

Expression of the telomerase catalytic subunit hTERT was quantified with reverse transcription PCR in the radioresistant colorectal cancer cell line SW620 following exposure to 5Gy of radiation. Additionally, 52 rectal cancer cases were pre-operatively treated with either the short (n = 19) or long (n = 33) course radiotherapy (SCR, LCR, respectively) regimes, before and after which their hTERT expressions were semi-quantified with immunohistochemistry (IHC). This was correlated with the histological tumour regression in the resected bowel, dichotomised into good and poor responses.

RESULTS

SW620 cells expressed gradually increasing levels of hTERT after radiation. hTERT IHC positivity of ≤75% tumour cells in pre-radiotherapied cancer was the optimal negative cut-off level [sensitivity 63.2%, specificity 45.8%, area under curve (AUC) 0.5362] in predicting good tumour response. As significantly more LCR cases showed good tumour response (p<0.0001), the SCR cases were excluded and AUC re-analysed, which still remained low (0.5357).

CONCLUSIONS

While our in vitro results suggest that hTERT up-regulation may contribute to radiation resistance of colorectal cancer cells, our in vivo results demonstrated poor ability of hTERT IHC in predicting histological tumour regression in rectal cancer.

摘要

目的

探讨端粒酶作为直肠癌放疗反应预测标志物的作用。

方法

采用逆转录 PCR 法检测耐辐射结直肠癌细胞系 SW620 中端粒酶催化亚单位 hTERT 在接受 5Gy 照射后的表达情况。另外,52 例直肠癌患者分别接受短程(n=19)或长程(n=33)放疗(分别为 SCR 和 LCR)治疗,在治疗前后采用免疫组化法(IHC)对其 hTERT 表达进行半定量检测。并将 hTERT 表达与切除肠段的组织学肿瘤消退程度相关联,分为良好和不良反应。

结果

SW620 细胞在接受辐射后 hTERT 表达逐渐增加。放疗前 hTERT IHC 阳性肿瘤细胞比例≤75%是预测良好肿瘤反应的最佳阴性截断值(敏感性 63.2%,特异性 45.8%,曲线下面积(AUC)0.5362)。由于 LCR 组中更多的病例显示出良好的肿瘤反应(p<0.0001),排除 SCR 组后重新分析 AUC,其值仍较低(0.5357)。

结论

虽然我们的体外结果表明 hTERT 的上调可能有助于结直肠癌细胞的辐射抵抗,但我们的体内结果表明 hTERT IHC 预测直肠癌组织学肿瘤消退的能力较差。

相似文献

1
Telomerase expression as a predictive marker of radiotherapy response in rectal cancer.端粒酶表达作为预测直肠癌放疗反应的标志物。
Pathology. 2012 Apr;44(3):209-15. doi: 10.1097/PAT.0b013e3283511cd5.
2
Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma.端粒酶亚基人端粒酶逆转录酶在结直肠癌患者肿瘤组织和非肿瘤黏膜中的预后潜力
Cancer. 2002 Nov 15;95(10):2103-11. doi: 10.1002/cncr.10939.
3
Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR.端粒酶作为乳腺癌的预后标志物:hTERT和hTR的高通量组织微阵列分析
J Pathol. 2002 Oct;198(2):181-9. doi: 10.1002/path.1191.
4
[Detection of telomerase activity by semi-quantitative and in situ assays and quantification of hTERT expression in bladder carcinomas].[通过半定量和原位检测法检测端粒酶活性以及对膀胱癌中hTERT表达进行定量分析]
Prog Urol. 2003 Apr;13(2):238-45.
5
[Relationship between human telomerase reverse transcriptase transcriptional level and telomerase activity in three ovarian cancer cell lines].[三种卵巢癌细胞系中人端粒酶逆转录酶转录水平与端粒酶活性的关系]
Ai Zheng. 2003 May;22(5):486-91.
6
Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer.结直肠癌患者血浆中人端粒酶逆转录酶(hTERT)mRNA的实时定量分析
Colorectal Dis. 2004 Jul;6(4):236-42. doi: 10.1111/j.1463-1318.2004.00627.x.
7
The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer.端粒酶活性及hTERT基因表达可作为人类卵巢癌抗癌治疗的指标。
Eur J Obstet Gynecol Reprod Biol. 2007 Feb;130(2):249-57. doi: 10.1016/j.ejogrb.2006.01.028. Epub 2006 Mar 7.
8
[Clinical significance of human telomerase reverse transcriptase in patients with colon cancer].人端粒酶逆转录酶在结肠癌患者中的临床意义
Ai Zheng. 2004 Nov;23(11 Suppl):1502-7.
9
Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.在接受根治性切除的非小细胞肺癌中,人端粒酶逆转录酶(hTERT)mRNA表达增加但端粒酶活性与生存无关。
Anticancer Res. 2009 Apr;29(4):1157-62.
10
Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.转录因子E2F1和端粒酶在胶质母细胞瘤中的表达:机制联系及预后意义
J Natl Cancer Inst. 2005 Nov 2;97(21):1589-600. doi: 10.1093/jnci/dji340.

引用本文的文献

1
Telomerase targeting as a therapeutic approach for sensitizing cancer cells to radiotherapy.靶向端粒酶作为一种使癌细胞对放疗敏感的治疗方法。
Mol Biol Rep. 2025 Jun 30;52(1):654. doi: 10.1007/s11033-025-10762-2.
2
Multiple Actions of Telomerase Reverse Transcriptase in Cell Death Regulation.端粒酶逆转录酶在细胞死亡调控中的多种作用
Biomedicines. 2023 Apr 4;11(4):1091. doi: 10.3390/biomedicines11041091.
3
Telomerase and drug resistance in cancer.端粒酶与癌症中的耐药性
Cell Mol Life Sci. 2017 Nov;74(22):4121-4132. doi: 10.1007/s00018-017-2573-2. Epub 2017 Jun 16.
4
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.新型人端粒酶逆转录酶(hTERT)肽疫苗用于转移性激素初治前列腺癌男性患者的I/IIa期临床试验
Cancer Immunol Immunother. 2017 Jul;66(7):891-901. doi: 10.1007/s00262-017-1994-y. Epub 2017 Apr 8.
5
AEG-1 expression is an independent prognostic factor in rectal cancer patients with preoperative radiotherapy: a study in a Swedish clinical trial.AEG-1表达是术前放疗直肠癌患者的独立预后因素:一项瑞典临床试验研究
Br J Cancer. 2014 Jul 8;111(1):166-73. doi: 10.1038/bjc.2014.250. Epub 2014 May 29.